BindingDB logo
myBDB logout

39 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
28105277 33 Design and Synthesis of Novel Meta-Linked Phenylglycine Macrocyclic FVIIa Inhibitors.EBI Bristol-Myers Squibb
27914800 11 Discovery of a new isomannide-based peptidomimetic synthetized by Ugi multicomponent reaction as human tissue kallikrein 1 inhibitor.EBI Universidade Federal Fluminense
27994741 48 Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors.EBI Bristol-Myers Squibb R&D
27612545 37 Synthesis and P1' SAR exploration of potent macrocyclic tissue factor-factor VIIa inhibitors.EBI Bristol-Myers Squibb Research& Development
27455395 66 Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex.EBI Bristol-Myers Squibb R&D
27015008 51 Atropisomer Control in Macrocyclic Factor VIIa Inhibitors.EBI Bristol-Myers Squibb Research& Development
26848109 8 The natural flavone fukugetin as a mixed-type inhibitor for human tissue kallikreins.EBI Campus Inc
26704266 80 Novel phenylalanine derived diamides as Factor XIa inhibitors.EBI Bristol-Myers Squibb Company
26151189 56 Structure-Based Design of Macrocyclic Coagulation Factor VIIa Inhibitors.EBI TBA
26005539 23 Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2' Moiety.EBI Bristol-Myers Squibb
25728130 79 Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties.EBI Bristol-Myers Squibb Company
24224573 31 Optimization of O3-acyl kojic acid derivatives as potent and selective human neutrophil elastase inhibitors.EBI Universidade de Lisboa
23294255 114 Development of new cyclic plasmin inhibitors with excellent potency and selectivity.EBI Philipps University Marburg
22607152 7 Kallikrein protease activated receptor (PAR) axis: an attractive target for drug development.EBI Universit£ degli Studi di Napoli Federico II
22386244 4 Human kallikrein 6 inhibitors with a para-amidobenzylanmine P1 group identified through virtual screening.EBI Sanofi Pharmaceuticals
10669559 180 Protease inhibitors: current status and future prospects.EBI University of Queensland
9301673 234 Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine.EBI Klinikum der Friedrich-Schiller-Universit£t Jena
1527787 11 Synthesis and biological activity of ketomethylene pseudopeptide analogues as thrombin inhibitors.EBI Thrombosis Research Institute
10915051 43 The design and synthesis of thrombin inhibitors: analogues of MD805 containing non-polar surrogates for arginine at the P1 position.EBI Novartis Horsham Research Centre
10091673 21 Synthesis of potent and selective inhibitors of human plasma kallikrein.EBI The Procter& Gamble Company
22047802 8 The arginine mimickingß-amino acidß³hPhe(3-H2N-CH2) as S1 ligand in cyclotheonamide-basedß-tryptase inhibitors.EBI Universit£t Bielefeld
 78 Synthesis and evaluation of 2-aryl-4H-3,1-benzoxazin-4-ones as C1r serine protease inhibitorsEBI TBA
15801822 28 9-hydroxyazafluorenes and their use in thrombin inhibitors.EBI Merck Research Laboratories
15582418 103 Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties.EBI Abbott Laboratories
15149645 92 Interaction with the S1 beta-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors.EBI Abbott Laboratories
15080981 72 N,N-Dialkylated 4-(4-arylsulfonylpiperazine-1-carbonyl)-benzamidines and 4-((4-arylsulfonyl)-2-oxo-piperazin-1-ylmethyl)-benzamidines as potent factor Xa inhibitors.EBI Millennium Pharmaceuticals, Inc.
15013006 69 Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs.EBI Millennium Pharmaceuticals, Inc.
14980671 78 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 3: Design, synthesis and SAR of orally bioavailable benzamidine-P4 inhibitors.EBI Millennium Pharmaceuticals Inc.
14980670 107 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 2: A survey of P4 motifs.EBI Millennium Pharmaceuticals Inc.
12039584 59 Design, synthesis, and SAR of monobenzamidines and aminoisoquinolines as factor Xa inhibitors.EBI Millennium Pharmaceuticals, Inc.
12039583 140 Design, synthesis and biological activity of novel non-amidine factor Xa inhibitors. Part 1: P(1) structure-activity relationships of the substituted 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides.EBI Millennium Pharmaceuticals, Inc.
10425106 12 4-Heterocyclohexanone-based inhibitors of the serine protease plasmin.EBI Brown University
9873535 13 Highly efficient and versatile synthesis of libraries of constrained beta-strand mimetics.EBI Molecumetics Ltd.
7739010 118 Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin.EBI Thrombosis Research Institute
7629790 32 New orally active serine protease inhibitors.EBI Minase Research Institute
2136920 39 New leupeptin analogues: synthesis and inhibition data.EBI University of Arkansas
24058293 12 Modulation of global low-frequency motions underlies allosteric regulation: demonstration in CRP/FNR family transcription factors.BDB Durham University
11784141 11 Beta-strand mimicking macrocyclic amino acids: templates for protease inhibitors with antiviral activity.BDB University of Queensland